Clinical Efficacy of Intravitreal Conbercept for the Treatment Macular Edema secondary to Branch Retinal Vein Occlusion

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16009191

Enrollment

Unknown

Registered

2016-09-11

Start date

2016-09-09

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retina branch vein occlusion

Interventions

2:conbercept

1:Lucentis

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: newly diagnosed BRVO with macula edema Best-corrected visual acuity (BCVA) was less than 20/32 ;central macular thickness (CMT) was =275µm by optical coherence tomography(OCT) examination

Exclusion criteria

Exclusion criteria: existence of vitreomacular traction or epiretinal membrane; a history of vitreous surgery and/or intravitreal injection of any VEGF antagonist or steroids; a history of glaucoma, diabetic retinopathy, uveitis.

Design outcomes

Primary

Measure	Time frame
VISUAL ACUITY;	—

Countries

China

Contacts

Public ContactBojun Zhao

Shangdong Provincial Hospital

bojunzhao0708@sina.com+86 15168860708

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026